Brief report
Short-term hemodynamic effect of a new oral PGI2 analogue, Beraprost, in primary and secondary pulmonary hypertension

https://doi.org/10.1016/S0002-9149(96)90408-7Get rights and content

Abstract

We conclude that Beraprost appears to be an effective and possibly available substitute for intravenous vasodilators in the treatment of primary PH and secondary PH. This preliminary report may offer favorable hemodynamic effects of a new oral PGI2 analogue in patients with PH.

References (13)

There are more references available in the full text version of this article.

Cited by (89)

  • Systemic sclerosis

    2019, Genomic and Precision Medicine: Infectious and Inflammatory Disease
  • Systemic Sclerosis

    2013, Genomic and Personalized Medicine
  • Systemic Sclerosis

    2012, Genomic and Personalized Medicine
  • Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension

    2012, Journal of Cardiology
    Citation Excerpt :

    The clinical effects of iloprost are similar to epoprostenol and treprostinil, and superior to them with regard to inducible infections. Beraprost was the first oral drug for PAH [20,21], although its effects subside after half a year of use. Therefore, beraprost has only been approved and used in Japan.

  • Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs

    2011, Respiratory Medicine
    Citation Excerpt :

    An oral formulation of treprostinil has been developed by United Therapeutics; however, this formulation has not yet been approved in the United States and is currently undergoing assessment in clinical trials.16,71–73 Similarly, beraprost (Procyclin®) has launched in Japan and Korea by Kaken Pharmaceuticals and is also undergoing assessment in the United States.74–85 The challenges of administration and adverse events associated with parenteral epoprostenol or treprostinil therapy (particularly the IV route) occasionally necessitate switching therapy, either from one analog to another or from prostaglandin analog therapy to another drug class, such as endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.

View all citing articles on Scopus
1

Dr. Saji's address is: Department of Pediatrics, Toho University, 6-11-1, Omorinisi, Ota-ku, Tokyo, 143, Japan.

View full text